Johnson Financial Group Inc (Wisconsin)’s Cartesian Therapeutics RNAC Stock Holding History

Johnson Financial Group Inc (Wisconsin)’s Portfolio RNAC Stock Details RNAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-4,618	Closed	-$89.2K	–	930
2024 Q4	$89.2K	Hold	4,618	–	–	﹤0.01%	386
2024 Q3	$74.4K	Buy	+4,618	New	+$72.2K	﹤0.01%	478

Other funds holding RNAC

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Johnson Financial Group Inc (Wisconsin)'s RNAC Position: Q1 2025 in Review

Johnson Financial Group Inc (Wisconsin) sold out of Cartesian Therapeutics (RNAC) in Q1 2025, closing a stake of 4,618 shares — an estimated $89.2K sold.

Johnson Financial Group Inc (Wisconsin) first reported a position in RNAC in Q3 2024 and held it in 2 quarters. The position peaked at $89.2K in Q4 2024. 72 funds tracked by Wall St. Rank hold RNAC as of Q1 2025.

Johnson Financial Group Inc (Wisconsin) reported no remaining Cartesian Therapeutics position as of Q1 2025 after selling out during the quarter.
Johnson Financial Group Inc (Wisconsin) sold 4,618 Cartesian Therapeutics shares in Q1 2025, an estimated $89.2K.
Johnson Financial Group Inc (Wisconsin) first reported a position in Cartesian Therapeutics in Q3 2024 and held it in 2 quarters.
Johnson Financial Group Inc (Wisconsin)'s Cartesian Therapeutics position peaked at $89.2K in Q4 2024.
72 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2025.

Based on Johnson Financial Group Inc (Wisconsin)'s 13F filing for Q1 2025, filed 15 May 2025.